Global Anti-PD-1 MAb Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Anti-PD-1 MAb market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Anti-PD-1 MAb is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Anti-PD-1 MAb is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Anti-PD-1 MAb market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Anti-PD-1 MAb is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Anti-PD-1 MAb market include Thermo Fisher Scientific, Merck KGaA, Ximbio, Sino Biological, OriGene Technologies, Leinco Technologies, Elabscience and BioVision, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Anti-PD-1 MAb, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Anti-PD-1 MAb, also provides the value of main regions and countries. Of the upcoming market potential for Anti-PD-1 MAb, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Anti-PD-1 MAb revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Anti-PD-1 MAb market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Anti-PD-1 MAb company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Anti-PD-1 MAb Segment by Company
Thermo Fisher Scientific
Merck KGaA
Ximbio
Sino Biological
OriGene Technologies
Leinco Technologies
Elabscience
BioVision
Anti-PD-1 MAb Segment by Type
1mg
2.5mg
Others
Anti-PD-1 MAb Segment by Application
Pharmaceutical
Research
Other
Anti-PD-1 MAb Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Anti-PD-1 MAb status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Anti-PD-1 MAb key companies, revenue, market share, and recent developments.
3. To split the Anti-PD-1 MAb breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Anti-PD-1 MAb market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Anti-PD-1 MAb significant trends, drivers, influence factors in global and regions.
6. To analyze Anti-PD-1 MAb competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-PD-1 MAb market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-PD-1 MAb and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-PD-1 MAb.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-PD-1 MAb industry.
Chapter 3: Detailed analysis of Anti-PD-1 MAb company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Anti-PD-1 MAb in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Anti-PD-1 MAb in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
According to APO Research, the global Anti-PD-1 MAb market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Anti-PD-1 MAb is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Anti-PD-1 MAb is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Anti-PD-1 MAb market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Anti-PD-1 MAb is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Anti-PD-1 MAb market include Thermo Fisher Scientific, Merck KGaA, Ximbio, Sino Biological, OriGene Technologies, Leinco Technologies, Elabscience and BioVision, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Anti-PD-1 MAb, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Anti-PD-1 MAb, also provides the value of main regions and countries. Of the upcoming market potential for Anti-PD-1 MAb, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Anti-PD-1 MAb revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Anti-PD-1 MAb market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Anti-PD-1 MAb company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Anti-PD-1 MAb Segment by Company
Thermo Fisher Scientific
Merck KGaA
Ximbio
Sino Biological
OriGene Technologies
Leinco Technologies
Elabscience
BioVision
Anti-PD-1 MAb Segment by Type
1mg
2.5mg
Others
Anti-PD-1 MAb Segment by Application
Pharmaceutical
Research
Other
Anti-PD-1 MAb Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Anti-PD-1 MAb status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Anti-PD-1 MAb key companies, revenue, market share, and recent developments.
3. To split the Anti-PD-1 MAb breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Anti-PD-1 MAb market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Anti-PD-1 MAb significant trends, drivers, influence factors in global and regions.
6. To analyze Anti-PD-1 MAb competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-PD-1 MAb market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-PD-1 MAb and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-PD-1 MAb.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-PD-1 MAb industry.
Chapter 3: Detailed analysis of Anti-PD-1 MAb company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Anti-PD-1 MAb in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Anti-PD-1 MAb in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Table of Contents
190 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Anti-PD-1 MAb Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Anti-PD-1 MAb Market Size (2020-2031)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Anti-PD-1 MAb Market Dynamics
- 2.1 Anti-PD-1 MAb Industry Trends
- 2.2 Anti-PD-1 MAb Industry Drivers
- 2.3 Anti-PD-1 MAb Industry Opportunities and Challenges
- 2.4 Anti-PD-1 MAb Industry Restraints
- 3 Anti-PD-1 MAb Market by Company
- 3.1 Global Anti-PD-1 MAb Company Revenue Ranking in 2024
- 3.2 Global Anti-PD-1 MAb Revenue by Company (2020-2025)
- 3.3 Global Anti-PD-1 MAb Company Ranking (2023-2025)
- 3.4 Global Anti-PD-1 MAb Company Manufacturing Base and Headquarters
- 3.5 Global Anti-PD-1 MAb Company Product Type and Application
- 3.6 Global Anti-PD-1 MAb Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Anti-PD-1 MAb Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.7.3 2024 Anti-PD-1 MAb Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
- 4 Anti-PD-1 MAb Market by Type
- 4.1 Anti-PD-1 MAb Type Introduction
- 4.1.1 1mg
- 4.1.2 2.5mg
- 4.1.3 Others
- 4.2 Global Anti-PD-1 MAb Sales Value by Type
- 4.2.1 Global Anti-PD-1 MAb Sales Value by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Anti-PD-1 MAb Sales Value by Type (2020-2031)
- 4.2.3 Global Anti-PD-1 MAb Sales Value Share by Type (2020-2031)
- 5 Anti-PD-1 MAb Market by Application
- 5.1 Anti-PD-1 MAb Application Introduction
- 5.1.1 Pharmaceutical
- 5.1.2 Research
- 5.1.3 Other
- 5.2 Global Anti-PD-1 MAb Sales Value by Application
- 5.2.1 Global Anti-PD-1 MAb Sales Value by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Anti-PD-1 MAb Sales Value by Application (2020-2031)
- 5.2.3 Global Anti-PD-1 MAb Sales Value Share by Application (2020-2031)
- 6 Anti-PD-1 MAb Regional Value Analysis
- 6.1 Global Anti-PD-1 MAb Sales Value by Region: 2020 VS 2024 VS 2031
- 6.2 Global Anti-PD-1 MAb Sales Value by Region (2020-2031)
- 6.2.1 Global Anti-PD-1 MAb Sales Value by Region: 2020-2025
- 6.2.2 Global Anti-PD-1 MAb Sales Value by Region (2026-2031)
- 6.3 North America
- 6.3.1 North America Anti-PD-1 MAb Sales Value (2020-2031)
- 6.3.2 North America Anti-PD-1 MAb Sales Value Share by Country, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Anti-PD-1 MAb Sales Value (2020-2031)
- 6.4.2 Europe Anti-PD-1 MAb Sales Value Share by Country, 2024 VS 2031
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Anti-PD-1 MAb Sales Value (2020-2031)
- 6.5.2 Asia-Pacific Anti-PD-1 MAb Sales Value Share by Country, 2024 VS 2031
- 6.6 South America
- 6.6.1 South America Anti-PD-1 MAb Sales Value (2020-2031)
- 6.6.2 South America Anti-PD-1 MAb Sales Value Share by Country, 2024 VS 2031
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Anti-PD-1 MAb Sales Value (2020-2031)
- 6.7.2 Middle East & Africa Anti-PD-1 MAb Sales Value Share by Country, 2024 VS 2031
- 7 Anti-PD-1 MAb Country-level Value Analysis
- 7.1 Global Anti-PD-1 MAb Sales Value by Country: 2020 VS 2024 VS 2031
- 7.2 Global Anti-PD-1 MAb Sales Value by Country (2020-2031)
- 7.2.1 Global Anti-PD-1 MAb Sales Value by Country (2020-2025)
- 7.2.2 Global Anti-PD-1 MAb Sales Value by Country (2026-2031)
- 7.3 USA
- 7.3.1 USA Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.3.2 USA Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.3.3 USA Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.4 Canada
- 7.4.1 Canada Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.4.2 Canada Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.4.3 Canada Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.5 Mexico
- 7.5.1 Mexico Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.5.2 Mexico Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.5.3 Mexico Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.6 Germany
- 7.6.1 Germany Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.6.2 Germany Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Germany Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.7 France
- 7.7.1 France Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.7.2 France Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.7.3 France Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.8 U.K.
- 7.8.1 U.K. Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.8.2 U.K. Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.8.3 U.K. Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.9 Italy
- 7.9.1 Italy Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.9.2 Italy Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.9.3 Italy Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.10 Spain
- 7.10.1 Spain Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.10.2 Spain Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.10.3 Spain Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.11 Russia
- 7.11.1 Russia Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.11.2 Russia Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Russia Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.12 Netherlands
- 7.12.1 Netherlands Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.12.2 Netherlands Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Netherlands Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.13.2 Nordic Countries Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Nordic Countries Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.14 China
- 7.14.1 China Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.14.2 China Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.14.3 China Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.15 Japan
- 7.15.1 Japan Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.15.2 Japan Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Japan Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.16 South Korea
- 7.16.1 South Korea Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.16.2 South Korea Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.16.3 South Korea Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.17 India
- 7.17.1 India Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.17.2 India Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.17.3 India Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.18 Australia
- 7.18.1 Australia Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.18.2 Australia Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.18.3 Australia Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.19.2 Southeast Asia Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.19.3 Southeast Asia Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.20 Brazil
- 7.20.1 Brazil Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.20.2 Brazil Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Brazil Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.21 Argentina
- 7.21.1 Argentina Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.21.2 Argentina Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Argentina Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.22 Chile
- 7.22.1 Chile Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.22.2 Chile Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Chile Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.23 Colombia
- 7.23.1 Colombia Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.23.2 Colombia Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Colombia Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.24 Peru
- 7.24.1 Peru Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.24.2 Peru Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Peru Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.25.2 Saudi Arabia Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Saudi Arabia Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.26 Israel
- 7.26.1 Israel Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.26.2 Israel Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Israel Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.27 UAE
- 7.27.1 UAE Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.27.2 UAE Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.27.3 UAE Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.28 Turkey
- 7.28.1 Turkey Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.28.2 Turkey Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Turkey Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.29 Iran
- 7.29.1 Iran Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.29.2 Iran Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.29.3 Iran Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 7.30 Egypt
- 7.30.1 Egypt Anti-PD-1 MAb Sales Value Growth Rate (2020-2031)
- 7.30.2 Egypt Anti-PD-1 MAb Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Egypt Anti-PD-1 MAb Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Thermo Fisher Scientific
- 8.1.1 Thermo Fisher Scientific Comapny Information
- 8.1.2 Thermo Fisher Scientific Business Overview
- 8.1.3 Thermo Fisher Scientific Anti-PD-1 MAb Revenue and Gross Margin (2020-2025)
- 8.1.4 Thermo Fisher Scientific Anti-PD-1 MAb Product Portfolio
- 8.1.5 Thermo Fisher Scientific Recent Developments
- 8.2 Merck KGaA
- 8.2.1 Merck KGaA Comapny Information
- 8.2.2 Merck KGaA Business Overview
- 8.2.3 Merck KGaA Anti-PD-1 MAb Revenue and Gross Margin (2020-2025)
- 8.2.4 Merck KGaA Anti-PD-1 MAb Product Portfolio
- 8.2.5 Merck KGaA Recent Developments
- 8.3 Ximbio
- 8.3.1 Ximbio Comapny Information
- 8.3.2 Ximbio Business Overview
- 8.3.3 Ximbio Anti-PD-1 MAb Revenue and Gross Margin (2020-2025)
- 8.3.4 Ximbio Anti-PD-1 MAb Product Portfolio
- 8.3.5 Ximbio Recent Developments
- 8.4 Sino Biological
- 8.4.1 Sino Biological Comapny Information
- 8.4.2 Sino Biological Business Overview
- 8.4.3 Sino Biological Anti-PD-1 MAb Revenue and Gross Margin (2020-2025)
- 8.4.4 Sino Biological Anti-PD-1 MAb Product Portfolio
- 8.4.5 Sino Biological Recent Developments
- 8.5 OriGene Technologies
- 8.5.1 OriGene Technologies Comapny Information
- 8.5.2 OriGene Technologies Business Overview
- 8.5.3 OriGene Technologies Anti-PD-1 MAb Revenue and Gross Margin (2020-2025)
- 8.5.4 OriGene Technologies Anti-PD-1 MAb Product Portfolio
- 8.5.5 OriGene Technologies Recent Developments
- 8.6 Leinco Technologies
- 8.6.1 Leinco Technologies Comapny Information
- 8.6.2 Leinco Technologies Business Overview
- 8.6.3 Leinco Technologies Anti-PD-1 MAb Revenue and Gross Margin (2020-2025)
- 8.6.4 Leinco Technologies Anti-PD-1 MAb Product Portfolio
- 8.6.5 Leinco Technologies Recent Developments
- 8.7 Elabscience
- 8.7.1 Elabscience Comapny Information
- 8.7.2 Elabscience Business Overview
- 8.7.3 Elabscience Anti-PD-1 MAb Revenue and Gross Margin (2020-2025)
- 8.7.4 Elabscience Anti-PD-1 MAb Product Portfolio
- 8.7.5 Elabscience Recent Developments
- 8.8 BioVision
- 8.8.1 BioVision Comapny Information
- 8.8.2 BioVision Business Overview
- 8.8.3 BioVision Anti-PD-1 MAb Revenue and Gross Margin (2020-2025)
- 8.8.4 BioVision Anti-PD-1 MAb Product Portfolio
- 8.8.5 BioVision Recent Developments
- 9 Concluding Insights
- 10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
